Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?

NCT ID: NCT01875692

Last Updated: 2014-12-03

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 286 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-10-31
• Study Completion Date: 2014-03-31

Brief Summary

Pathogens of ventilator-associated pneumonia (VAP) come from colonizers of the trachea. The hypothesis of the investigators is that during the first days of intubation, independently of the use of antibiotics, there is a change in the oro-pharyngeal flora leading to the selection of one pathogen in the trachea, that will finally be the cause of VAP.

The investigators designed a prospective study including 300 patients intubated for more than 3 days, with daily analysis of oro-pharyngeal juice and tracheal aspirate by culture and metagenomics, in order to determine if this microbiological surveillance permits:

1. To predict a high risk to develop a VAP in the next 48h and even to predict its agent

2. To better understand the development of VAP by studying the evolution of the "respiratory flora" in the context of intubation

Detailed Description

BACKGROUND OF THE STUDY:

The ventilator-associated pneumonia (VAP) is responsible for almost half of infections acquired in intensive care, affecting up to 28% of mechanically ventilated patients with a mortality rate ranging from 25 to 50%. The majority of these VAP originate in the sub-glottic juice that accumulates just above the endotracheal tube cuff. Many preventive measures exist and are applied in this institution, including oropharyngeal aspiration every 4 hours and tracheal aspirates every 8 hours. Currently, these aspirates are simply discarded. However, a French study evaluating the colonization and infection of the respiratory tract of patients with acute respiratory distress syndrome (ARDS) has highlighted that the causative agent of VAP is selected in more than 2/3 of the cases in tracheal aspirates several days before the VAP. This suggest that "microbiological surveillance" of daily aspirates may permit the identification of a selected respiratory pathogen later responsible of VAP.

Parallel to this, the rapid development of genomics has highlighted the role of flora (microbiota) and its link with disease (eg, colitis and intestinal microbiota inflammatory). This area is also emerging in the field of respiratory tract infections, for example in patients with chronic obstructive pulmonary disease (COPD) or asthma. There is no description yet of metagenomics changes in respiratory flora of patients intubated with or without VAP, neither evaluation of the benefits of such an approach in relation to classical microbiology. The investigators believe that studying the respiratory flora of ventilated patients could provide clues to better understand the development of VAP.

METHODOLOGY (plan, inclusion and objectives):

Prospective study of 300 intubated patients recruited during a period of 2 years, in whom tracheal aspirates and oropharyngeal juice collected daily will be analyzed by culture and metagenomics, instead of being simply discarded. The results of these analyzes will be used only for research purposes (culture and metagenomics in parallel).

The main objective is to determine whether daily monitoring of oropharyngeal juice and tracheal aspirates by culture identifies the selection of a pathogen among the colonizing flora, which would be predictive of the onset of VAP in 48-72 hours.

The secondary objectives are to obtain new knowledge on the kinetics of colonization and respiratory infections in intubated patients, compare the advantages and disadvantages of a metagenomic approach compared to culture in this context, and study the influence of antibiotherapy in this context.

Conditions

Pneumonia, Ventilator-Associated

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Patient hospitalised in the adult ICU of HUG (>18 years old)
• Intubated for < 24 hours
• Expected duration of intubation > 4 days (e.g. neurologic disease)

Exclusion Criteria

• Patients for whom regular tracheal aspirations cannot not be performed (because of unstable intracranial pressure, for example).
• New antibiotic therapy in the week preceding the intubation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Geneva

OTHER

Sponsor Role: lead

Responsible Party

Prof. Jacques SCHRENZEL

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jacques Schrenzel, Prof.

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Geneva

Locations

University Hospital

Geneva, Canton of Geneva, Switzerland

Countries

Switzerland

Other Identifiers

12-051

Identifier Type: -

Identifier Source: org_study_id